Tobira Therapeutics Inc. (NASDAQ:TBRA) dropped 1.2% during mid-day trading on Friday . The stock traded as low as $4.93 and last traded at $5.02, with a volume of 71,122 shares. The stock had previously closed at $5.08.

TBRA has been the topic of several research analyst reports. Cantor Fitzgerald cut shares of Tobira Therapeutics to a “buy” rating and set a $19.00 target price on the stock. in a research report on Monday, July 25th. Zacks Investment Research raised shares of Tobira Therapeutics from a “hold” rating to a “buy” rating and set a $13.00 target price on the stock in a research report on Wednesday, July 13th. HC Wainwright reissued a “buy” rating on shares of Tobira Therapeutics in a research report on Tuesday, June 28th. Cowen and Company reissued a “buy” rating on shares of Tobira Therapeutics in a research report on Tuesday, May 10th. Finally, Leerink Swann reissued a “buy” rating and issued a $18.00 target price on shares of Tobira Therapeutics in a research report on Tuesday, May 10th. Five analysts have rated the stock with a buy rating, Tobira Therapeutics currently has a consensus rating of “Buy” and an average price target of $16.75.

The firm’s market cap is $96.74 million. The firm’s 50-day moving average price is $5.65 and its 200 day moving average price is $8.17.

Tobira Therapeutics (NASDAQ:TBRA) last issued its quarterly earnings results on Tuesday, August 9th. The biopharmaceutical company reported ($0.71) EPS for the quarter, missing the consensus estimate of ($0.63) by $0.08. The business had revenue of $1.06 million for the quarter. Equities analysts predict that Tobira Therapeutics Inc. will post ($2.65) EPS for the current year.

In other Tobira Therapeutics news, major shareholder A/S Novo sold 66,814 shares of the business’s stock in a transaction dated Thursday, June 30th. The shares were sold at an average price of $13.04, for a total value of $871,254.56. Following the sale, the insider now directly owns 2,073,022 shares in the company, valued at $27,032,206.88. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

Tobira Therapeutics, Inc, formerly Regado Biosciences, Inc, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies to treat liver disease, inflammation, fibrosis and human immunodeficiency virus (HIV). The Company’s lead product candidate, cenicriviroc (CVC), is an immunomodulator and dual inhibitor of C-C Chemokine Receptor 2 (CCR2) and C-C Chemokine Receptor 5 (CCR5) being evaluated for the treatment of non-alcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC), and as an adjunctive therapy to standard of care in HIV.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.